Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Femasys Inc (FEMY)

Femasys Inc (FEMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,877
  • Shares Outstanding, K 58,480
  • Annual Sales, $ 1,630 K
  • Annual Income, $ -18,820 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta -2.53
  • Price/Sales 7.43
  • Price/Cash Flow N/A
  • Price/Book 5.66
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.72
  • Most Recent Earnings $-0.10 on 11/14/25
  • Next Earnings Date 03/26/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +434,447.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4702 +10.55%
on 02/12/26
0.5912 -12.08%
on 02/26/26
+0.0118 (+2.32%)
since 02/06/26
3-Month
0.4702 +10.55%
on 02/12/26
0.9494 -45.25%
on 12/15/25
-0.3602 (-40.93%)
since 12/05/25
52-Week
0.3067 +69.48%
on 08/26/25
1.7599 -70.46%
on 03/20/25
-0.9802 (-65.35%)
since 03/06/25

Most Recent Stories

More News
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access

-- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance -- ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:...

FEMY : 0.5244 (-0.68%)
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical...

FEMY : 0.5244 (-0.68%)
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products

ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to...

FEMY : 0.5244 (-0.68%)
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a leading biomedical innovator making fertility and non-surgical permanent birth control...

FEMY : 0.5244 (-0.68%)
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

ATLANTA , Jan. 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 0.5244 (-0.68%)
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

-- Innovative single-device solution integrates proven FemVue and FemChec ® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE)...

FEMY : 0.5244 (-0.68%)
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company’s...

PMCB : 0.7500 (+15.26%)
FEMY : 0.5244 (-0.68%)
Femasys Announces Third Quarter Financial Results for 2025

– FDA Approval to Advance Final FemBloc ® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway...

FEMY : 0.5244 (-0.68%)
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe

-- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets -- ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE)...

FEMY : 0.5244 (-0.68%)
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured...

FEMY : 0.5244 (-0.68%)

Business Summary

Femasys Inc.is a biomedical company focused on transforming women's healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The company's lead product candidates offer FemBloc and FemaSeed. Femasys Inc. is based in ATLANTA.

See More

Key Turning Points

3rd Resistance Point 0.6137
2nd Resistance Point 0.5893
1st Resistance Point 0.5587
Last Price 0.5244
1st Support Level 0.5037
2nd Support Level 0.4793
3rd Support Level 0.4487

See More

52-Week High 1.7599
Fibonacci 61.8% 1.2048
Fibonacci 50% 1.0333
Fibonacci 38.2% 0.8618
Last Price 0.5244
52-Week Low 0.3067

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar